English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Correspondence: Martin H Bluth Department of Pathology, Wayne State University School of Medicine, Detroit Medical Center, Karmanos Cancer Institute, Detroit, MI 48201, USA Email mbluth@med.wayne.edu The layperson’s depiction of people preservation often conjures up nefarious iterations of Jack Finney’s 1954 novel, The Body Snatchers, or Ira Levin’s thriller, The Boys from Brazil, where maintenance of human composition is employed for perpetuation of ill repute. Recent illustrations of animal preservation-reanimation gone wrong, such as the Jurassic Park films, further echoed such concerns. In contrast, during the 1980s, the advent of cloning morphed with cryopreservation to furnish jocularity in the form of many an Arnold Schwarzenegger film (Twins, Junior). The late 1980s and early 1990s also demonstrated a greater degree of reality-based cryopreservation, public acceptance, and clinical application in the form of cord blood-banking, stem cell transplantation, and in-situ fertilization technologies, thus positively affecting both the biobanking image and human health. So where are we now? In the last decade or so, tissue and fluid preservation, also known as biobanking, biorepository science, or cryopreservation – often referred to as cryobanking – has become mainstream and big business. According to research by the British Broadcasting Corporation, the global biobanking market in 2010 was over $140 billion dollars, with a projected 30% increase by the year 2015 towards fostering biobanking initiatives. The basic idea behind biobanking is straightforward: collect and store tissues obtained from patients with select disease and, in time, you will have access to thousands of specimens to perform the interrogation of choice. These can include but are not limited to: biomarker discovery, pre/post-drug monitoring, disease prognostication, population screening, and sex/race/ethnicity demographics. The stem cell explosion, where reports increasingly suggest that stem cells exist in almost any organ, with the added potentiality of being able to regrow any diseased or damaged organ, provides perfectly poised positioning for the cryobanking industry to regrow a new you from an earlier cellular version of your deep frozen self. Such strategies have been implemented into the animal-based food industry. The possibilities appear to be limited to the imagination. But there are a few hard strops along the way: cost is a major issue. One needs to project the type of bank (disease-specific?), tissues collected (body fluids versus solid tissues and their tributaries), rate of collection, anticipated sample size, collection logic (transport), overhead, labor, time, heating and cooling, structural edification, equipment and maintenance costs, and real estate, among others, to determine what type of infrastructure is necessary. Dovepress

Cryobanking: the brave new world of biobanking and specimen cryopreservation